Development of two 410-cancer-gene panel tests for solid tumors and liquid biopsy based on genome data of 5,143 Japanese cancer patients

Abstract

Next-generation sequencing (NGS) is an integral part of precision medicine, and its power for detecting comprehensive genetic alterations may contribute to treatment decisions for patients with advanced, recurrent, or metastatic cancer. An NGS oncology panel developed in the U.S. and Europe, which targets cancer-related genes, has been approved in Japan, and testing is becoming more widespread in clinical oncology practice. However, these panels are based on cancer-related genes selected from cancer databases of Westerners. We aimed to develop an onco-panel for Japanese. We designed two High-tech Omics-based Patient Evaluation (HOPE) onco-panels: HOPE onco-panel Solid for solid tumors and HOPE onco-panel Liquid for liquid biopsy. These were based on genomic information of 5,143 cancer cases in the Japanese Cancer Genome Atlas (JCGA), a database of Japanese cancer cases. Their performance was confirmed using clinical data.

Molecular characterization‐based multi‐omics analyses in primary liver cancer using the Japanese version of the genome atlas

“…Based on the results of the WES study, we recently reported the development of our own custom cancer panel. 34 This panel is also designed to search for TERT promoter regions and FGFR fusion genes. We are just starting our analysis using the panel and will report the results in the future.…”

“…The present report is part of the results of a pan‐cancer sequencing study by WES, which has not been able to search for genetic alterations outside of the exon region. Based on the results of the WES study, we recently reported the development of our own custom cancer panel 34 . This panel is also designed to search for TERT promoter regions and FGFR fusion genes.…”